A PET study of effects of chronic 3,4‐methylenedioxymethamphetamine (MDMA, “ecstasy”) on serotonin markers in Göttingen minipig brain

The psychostimulant 3,4‐methylendioxymethamphetamine (MDMA, “ecstasy”) evokes degeneration of telencephalic serotonin innervations in rodents, nonhuman primates, and human recreational drug users. However, there has been no alternative to nonhuman primates for studies of the cognitive and neurochemical consequences of serotonin depletion in a large‐bodied animal. Therefore, we used positron emission tomography (PET) with [11C]DASB to map the distribution of plasma membrane serotonin transporters in brain of Göttingen minipigs, first in a baseline condition, and again at 2 weeks after treatment with MDMA (i.m.), administered at a range of doses. In parallel PET studies, [11C]WAY‐100635 was used to map the distribution of serotonin 5HT1A receptors. The acute MDMA treatment in awake pigs evoked 1°C of hyperthermia. MDMA at total doses greater than 20 mg/kg administered over 2–4 days reduced the binding potential (pB) of [11C]DASB for serotonin transporters in porcine brain. A mean total dose of 42 mg/kg MDMA in four animals evoked a mean 32% decrease in [11C]DASB pB in mesencephalon and diencephalon, and a mean 53% decrease in telencephalic structures. However, this depletion of serotonin innervations was not associated with consistent alterations in the binding of [11C]WAY‐100635 to serotonin 5HT1A receptors. Stereological cell counting of serotonin‐positive neurons, which numbered 95,000 in the dorsal raphé nucleus of normal animals, was unaffected in MDMA‐treated group. group. Synapse 61:478–487, 2007. © 2007 Wiley‐Liss, Inc.

[1]  M. Colado,et al.  Studies on the role of dopamine in the degeneration of 5‐HT nerve endings in the brain of Dark Agouti rats following 3,4‐methylenedioxymethamphetamine (MDMA or ‘ecstasy’) administration , 1999, British journal of pharmacology.

[2]  F. Turkheimer,et al.  On the Undecidability among Kinetic Models: From Model Selection to Model Averaging , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  G. Ricaurte,et al.  Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations. , 1992, The Journal of pharmacology and experimental therapeutics.

[4]  L. Reneman,et al.  The Acute and Chronic Effects of MDMA (“Ecstasy”) on Cortical 5-HT2A Receptors in Rat and Human Brain , 2002, Neuropsychopharmacology.

[5]  M. Jurima‐Romet,et al.  Evidence for the catalysis of dextromethorphan O-demethylation by a CYP2D6-like enzyme in pig liver. , 2000, Toxicology in vitro : an international journal published in association with BIBRA.

[6]  A. Gjedde,et al.  MDMA‐evoked changes in cerebral blood flow in living porcine brain: Correlation with hyperthermia , 2004, Synapse.

[7]  A. Gjedde,et al.  Normalization of markers for dopamine innervation in striatum of MPTP‐lesioned miniature pigs with intrastriatal grafts , 2001, Acta neurologica Scandinavica.

[8]  F. Wappler,et al.  Induction of Malignant Hyperthermia in Susceptible Swine by 3,4-Methylenedioxymethamphetamine (“Ecstasy”) , 2003, Anesthesiology.

[9]  M. Colado,et al.  The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) , 2003, Pharmacological Reviews.

[10]  R Myers,et al.  Effect of 5‐HT on binding of [11C] WAY 100635 to 5‐HT1A receptors in rat brain, assessed using in vivo microdialysis and PET after fenfluramine , 2001, Synapse.

[11]  J. Langston,et al.  Nigrostriatal Reduction of Aromatic L‐Amino Acid Decarboxylase Activity in MPTP‐Treated Squirrel Monkeys: In Vivo and In Vitro Investigations , 2000, Journal of neurochemistry.

[12]  R. de la Torre,et al.  Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis. , 2002, Journal of analytical toxicology.

[13]  John F. Young,et al.  Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. , 2003, Neurotoxicology.

[14]  Flemming Andersen,et al.  MR-Based Statistical Atlas of the Göttingen Minipig Brain , 2001, NeuroImage.

[15]  G. Battaglia,et al.  MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons , 1988, Pharmacology Biochemistry and Behavior.

[16]  L. Seiden,et al.  Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. , 1996, The Journal of pharmacology and experimental therapeutics.

[17]  H. Gundersen Stereology of arbitrary particles * , 1986, Journal of microscopy.

[18]  J. Fisk,et al.  Verbal working memory deficits in current and previous users of MDMA , 2004, Human psychopharmacology.

[19]  Jan Corfixen Sørensen,et al.  The DaNeX Study of Embryonic Mesencephalic, Dopaminergic Tissue Grafted to a Minipig Model of Parkinson's Disease: Preliminary Findings of Effect of MPTP Poisoning on Striatal Dopaminergic Markers 1 , 2000, Cell transplantation.

[20]  R. Glennon,et al.  Identification of metabolites of 3,4-methylenedioxymethamphetamine in rats. , 1990, Drug and alcohol dependence.

[21]  J. Robinson,et al.  Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence? , 2001, Psychopharmacology.

[22]  R. Foltz,et al.  In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. , 1988, Chemical research in toxicology.

[23]  G. Ricaurte,et al.  Reorganization of ascending 5-HT axon projections in animals previously exposed to the recreational drug (+/-)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[24]  H. J. G. Gundersen,et al.  The new stereological tools: Disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis , 1988, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[25]  M. Casu,et al.  Immunocytochemical study of the forebrain serotonergic innervation in Sardinian alcohol-preferring rats , 2004, Psychopharmacology.

[26]  S. Kish How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy? , 2002, Pharmacology Biochemistry and Behavior.

[27]  Sung-Cheng Huang,et al.  Linear regression with spatial constraint to generate parametric images of ligand-receptor dynamic PET studies with a simplified reference tissue model , 2003, NeuroImage.

[28]  M. Farré,et al.  Pharmacology of MDMA in Humans , 2000, Annals of the New York Academy of Sciences.

[29]  John Hilton,et al.  Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .

[30]  G. Ricaurte,et al.  Behavioral and Neurochemical Consequences of Long-Term Intravenous Self-Administration of MDMA and Its Enantiomers by Rhesus Monkeys , 2004, Neuropsychopharmacology.

[31]  C. Friis,et al.  Is cytochrome P450 CYP2D activity present in pig liver? , 2002, Pharmacology & toxicology.

[32]  J R Nyengaard,et al.  Tissue shrinkage and unbiased stereological estimation of particle number and size * , 2001, Journal of microscopy.

[33]  M. Wilson,et al.  Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine , 1989, Neuroscience.

[34]  R. Croft,et al.  Chronic MDMA (ecstasy) use, cognition and mood , 2004, Psychopharmacology.

[35]  U. McCann,et al.  Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) users: a controlled study , 1999, Psychopharmacology.

[36]  Ralph Buchert,et al.  A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters. , 2004, The American journal of psychiatry.

[37]  H. Wikström,et al.  Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635 , 1997, Brain Research.

[38]  R. de la Torre,et al.  Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. , 2000, British journal of clinical pharmacology.

[39]  E. Azmitia,et al.  Cellular Localization of the 5-HT1A Receptor in Primate Brain Neurons and Glial Cells , 1996, Neuropsychopharmacology.

[40]  H. Pakkenberg,et al.  MPTP-induced Parkinsonism in minipigs: A behavioral, biochemical, and histological study. , 1999, Neurotoxicology and teratology.

[41]  P. Cumming,et al.  Pig brain stereotaxic standard space: Mapping of cerebral blood flow normative values and effect of MPTP-lesioning , 2005, Brain Research Bulletin.

[42]  G. Battaglia,et al.  Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  M. Wilson,et al.  (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates. , 1988, JAMA.

[44]  André Luxen,et al.  Effect of endogenous serotonin on the binding of the 5‐HT1A PET ligand 18F‐MPPF in the rat hippocampus: kinetic β measurements combined with microdialysis , 2002, Journal of neurochemistry.

[45]  R. de la Torre,et al.  Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. , 2004, Therapeutic drug monitoring.

[46]  Latifa Rbah,et al.  Displacement of the PET ligand 18F‐MPPF by the electrically evoked serotonin release in the rat hippocampus , 2003, Synapse.

[47]  R. de la Torre,et al.  Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. , 2004, Trends in pharmacological sciences.

[48]  R. Buchert,et al.  Specific neurotoxicity of chronic use of ecstasy. , 2002, Toxicology letters.

[49]  A. García-Osta,et al.  Differential Regulation by Methylenedioxymethamphetamine of 5‐Hydroxytryptamine1A Receptor Density and mRNA Expression in Rat Hippocampus, Frontal Cortex, and Brainstem: The Role of Corticosteroids , 1997, Journal of neurochemistry.

[50]  T Suhara,et al.  In vivo binding properties of [carbonyl‐11C]WAY‐100635: Effect of endogenous serotonin , 2001, Synapse.

[51]  R. Buchert,et al.  Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective , 2006, Journal of psychopharmacology.

[52]  Z. Szabo,et al.  In vivo detection of short‐ and long‐term MDMA neurotoxicity—a positron emission tomography study in the living baboon brain , 1998, Synapse.

[53]  Alan A. Wilson,et al.  [11C]‐NS 4194 versus [11C]‐DASB for PET imaging of serotonin transporters in living porcine brain , 2003, Synapse.

[54]  E. D. De Souza,et al.  3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. , 1987, The Journal of pharmacology and experimental therapeutics.

[55]  Liesbeth Reneman,et al.  Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons , 2001, The Lancet.

[56]  Steen Jakobsen,et al.  Mapping the amphetamine-evoked dopamine release in the brain of the Göttingen minipig , 2005, Brain Research Bulletin.

[57]  Steen Jakobsen,et al.  Behavioral response to novelty correlates with dopamine receptor availability in striatum of Göttingen minipigs , 2005, Behavioural Brain Research.

[58]  Zsolt Szabo,et al.  Quantitative PET Studies of the Serotonin Transporter in MDMA Users and Controls Using [11C]McN5652 and [11C]DASB , 2005, Neuropsychopharmacology.

[59]  U. McCann,et al.  Pharmacokinetic Profile of Single and Repeated Oral Doses of MDMA in Squirrel Monkeys: Relationship to Lasting Effects on Brain Serotonin Neurons , 2006, Neuropsychopharmacology.

[60]  A. R. Green,et al.  Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA (‘Ecstasy’) to rats , 1994, Neuropharmacology.

[61]  B. Yamamoto,et al.  Ascorbic acid prevents 3,4‐methylenedioxymethamphetamine (MDMA)‐induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5‐HT , 2001, Synapse.

[62]  Albert Gjedde,et al.  MDMA‐evoked changes in [11C]raclopride and [11C]NMSP binding in living pig brain , 2004, Synapse.

[63]  Victor W. Pike,et al.  Remotely-controlled production of the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635, via 11C-carboxylation of an immobilized Grignard reagent , 1996 .

[64]  V. Sánchez,et al.  Effect of Repeated (‘Binge’) Dosing of MDMA to Rats Housed at Normal and High Temperature on Neurotoxicdamage to Cerebral 5-Ht and Dopamine Neurones , 2004, Journal of psychopharmacology.

[65]  Arne Møller,et al.  Quantitative [18F]Fluorodopa/PET and Histology of Fetal Mesencephalic Dopaminergic Grafts to the Striatum of MPTP-Poisoned Minipigs , 2002, Cell transplantation.